Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFO vs HFA propellant on mucociliary clearance
NCT05755932Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of HFO-1234ze(E) in asthma, chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Jun 2023; status: completed.
02
Drugs
HFO-1234ze(E)
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05755932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755932.